logo

Merrimack Pharmaceuticals, Inc. (MACK)



Trade MACK now with
  Date
  Headline
9/6/2018 6:51:02 AM Merrimack Completes Enrollment In Randomized Phase 2 SHERLOC Study Of MM-121 In NSCLC
8/7/2018 6:36:50 AM Merrimack Q2 Net Loss $17.8 Mln Or $1.33 Per Share Vs Net Loss $28.9 Mln Or $2.18 Per Share Last Year
6/25/2018 7:20:50 AM Merrimack Announces Top-Line Results From Randomized Phase 2 Trial Of MM-141 In Front-Line Metastatic Pancreatic Cancer
5/8/2018 6:27:26 AM Merrimack Pharma Q1 Net Loss From Operations $17.8 Mln Or $1.33/Shr Vs Loss $28.7 Mln Or $2.20/Shr Last Year
3/12/2018 6:30:20 AM Merrimack Pharma Q4 Loss Attributable To Cont Opns $11.8 Mln Or $0.89/Shr Vs Loss $40.1 Mln Or $2.93/Shr Last Year
3/12/2018 6:29:04 AM Merrimack Pharma Expands Enrollment In Ongoing Randomized Phase 2 SHERLOC Study Of MM-121 In Non-small Cell Lung Cancer
2/26/2018 6:57:02 AM Merrimack Doses First Patient In Randomized Phase 2 Clinical Study Of MM-121
11/30/2017 6:51:00 AM Merrimack Appoints George Demetri To Board Of Directors
11/8/2017 6:43:27 AM Merrimack Pharma Posts Q3 Net Loss Of $5.4 Mln Or $0.40/share
10/30/2017 7:00:56 AM Merrimack: FDA Granted Orphan Drug Designation To MM-121 For Treatment Of Heregulin Positive Non-small Cell Lung Cancer
8/9/2017 6:59:02 AM Merrimack Pharma Q2 Loss From Cont. Ops. Narrows To $28.9 Mln Or $0.22/shr From $51.4 Mln Or $0.41/shr Last Year
6/29/2017 6:01:22 AM Hercules Capital Announces Addl Portfolio Company Liquidity Events; Portfolio Companies Currently In IPO Registration
6/19/2017 6:56:35 AM Merrimack Completes Enrollment In Phase 2 CARRIE Study Of MM-141; Data Expected In First Half Of 2018
6/8/2017 6:57:01 AM Merrimack Appoints Sergio Santillana As Chief Medical Officer And Ellen Forest As Head Of Human Resources